Fate Therapeutics Inc. (FATE)
NASDAQ · Healthcare
Fate Therapeutics Inc. EBITDA 2011–2025
Fate Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2011 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Fate Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -30.1 M, a 20.73% decrease year-over-year.
- Fate Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -138.7 M, a 18.78% decrease year-over-year.
- Fate Therapeutics Inc. annual ebitda for 2025 was -134.8 M, a 29.54% decrease from 2024.
- Fate Therapeutics Inc. annual ebitda for 2024 was -191.3 M, a 11.08% increase from 2023.
- Fate Therapeutics Inc. annual ebitda for 2023 was -172.2 M, a 41.54% decrease from 2022.
- Fate Therapeutics Inc. annual ebitda for 2022 was -294.6 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Fate Therapeutics Inc. EBITDA — FAQ
Fate Therapeutics Inc. (FATE) ebitda over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see FATE's ebitda history?
The chart and table above show Fate Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.